Therapeutic drug monitoring of vancomycin in the real-world clinical practice of treating patients with deep suppuration after hip arthroplasty

Author:

Zhukova O. V.1ORCID,Komarov R. N.1ORCID,Mitrofanov V. N.1ORCID,Vorobeva O. A.1ORCID

Affiliation:

1. Privolzhsky Research Medical University

Abstract

Relevance. Vancomycin, like other glycopeptide antibiotics, is characterized by its pharmacokinetic and pharmacodynamic profile by both time-dependent and concentration-dependent bactericidal effect. Its optimal achievement is ensured by maintaining the drug concentration several times higher than the minimum inhibitory concentration (MIC). Exceeding peak concentrations of vancomycin (> 20 µg/ml) increase the risk of nephrotoxicity, and extremely low (<9.9 µg/ml) — selection of resistant forms of Gram-positive microorganisms.Objective of this study is to evaluate the achievement of target level of vancomycin concentration in plasma of patients with deep suppuration after hip arthroplasty based on therapeutic drug monitoring.Methods. The study included patients who received infusion therapy with vancomycin in the purulent department of traumatology and orthopedics of the University Clinic of the Privolzhsky Research Medical University for deep suppuration after hip arthroplasty in the period from 01.03.2023 to 30.06.2023. The study was conducted without correction for the trade name of vancomycin. Therapeutic drug monitoring was performed on the third day after the start of therapy (after the 4th administration). Blood sampling was performed 1 hour after infusion and 1 hour before subsequent infusion. Vancomycin in blood plasma was determined by high-performance liquid chromatography using a chromatograph "LC-20 Prominance" (Shimadzu, Japan) in reverse phase mode with matrix photodiode detector of UV and visible spectra (SPD–M20A).Results. A total of 14 patients were included in the study, including 6 males and 8 females. The mean age of the patients was 60.36±12.38 years. Bacterial flora was detected in all patients included in the study. Resistant Gram-positive microorganisms were isolated: St. aureus (MRSA) — 5, in 9 patients — coagulase-negative staphylococci (St. epidermidis (MRSE) — 7, St. simulans — 2). Therapeutic concentrations of both initial and residual concentrations were achieved in 28.57% of cases. In 71.43% of cases residual concentrations had values <10 µg/ml, which corresponded to extremely low values, not sufficient for clinical effect associated with eradication of the pathogen at MPC = 1 µg/ml. At the same time initial concentrations of vancomycin were defined as extremely low in 14.29% of cases, and in 42.86% — as exceeding the therapeutic range. Vancomycin concentrations in the therapeutic range of 10 to 20 µg/ml 1 hour after infusion (initial concentrations) were determined in 42.86% of patients.Conclusion. The results of therapeutic drug monitoring of vancomycin in patients with deep suppuration after hip arthroplasty show a wide range of concentrations. A high proportion of residual concentrations at extremely low levels (<9.9 μg/ml) was observed, which is consistent with the results of other studies and confirms the need for therapeutic drug monitoring in every patient receiving vancomycin therapy.

Publisher

Publishing House OKI

Reference11 articles.

1. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009 Aug 1;49(3):325-7. doi: 10.1086/600877.

2. Rybak MJ, Le J, Lodise TP, et al. Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus Aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2020;71(6):1361-4. doi: 10.1093/cid/ciaa303.

3. He N, Su S, Ye Z, et al. Evidence-based Guideline for Therapeutic Drug Monitoring of Vancomycin: 2020 Update by the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. Clin Infect Dis. 2020 Dec 23;71(Suppl 4):S363-S71. doi: 10.1093/cid/ciaa1536.

4. Matsumoto K, Oda K, Shoji K, et al. Clinical Practice Guidelines for Therapeutic Drug Monitoring of Vancomycin in the Framework of Model-Informed Precision Dosing: A Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Pharmaceutics. 2022 Feb 23;14(3):489. doi: 10.3390/pharmaceutics14030489.

5. Ye ZK, Tang HL, Zhai SD. Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis. PLoS One. 2013 Oct 18;8(10):e77169. doi: 10.1371/journal.pone.0077169.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3